A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors. Background: Multiple lines of evidence suggest a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback